-
Expression and Prognostic Significance of SCHIP1 in Acute Myeloid Leukemia: Analysis Based on Bioinformatics
- XU Jie, WANG Kefei, WEI Xiaojing, GONG Lixin, JIAO Yang, QIU Lugui, HAO Mu*
-
2020, 10(4):
417-425.
DOI: 10.19586/j.2095-2341.2020.0019
-
Abstract (
)
PDF
(9206KB)(
)
The study was aimed to investigate the expression and clinical significance of schwannomin interacting protein 1 (SCHIP1) in patients with acute myeloid leukemia through data mining and bioinformatics analysis. First of all, a meta-analysis was performed on all AML data sets including the Oncomine database, which aimed to screen the target gene SCHIP1 and further analyze its expression changes in AML patients. Then, AML dataset source files containing survival information were downloaded from GEO database to analyze the prognostic effect of SCHIP1 on disease. And the expression of SCHIP1 among subgroup and the correlation with FLT3 gene mutation, PML/RARα fusion and RAS activation were analyzed using TCGA database. Ultimately, GEPIA2 was used to verify the expression and prognostic significance of SCHIP1 and its correlation with FLT3 and PML gene expression. Results showed that 44 AML datasets were included in Oncomine database, with a total of 3 534 sample data. And a total of 1 188 samples from 5 datasets contained mRNA expression data of "Cancer vs. Normal", and a meta-analysis of these samples showed that SCHIP1 was the 17th most highly expressed molecule. Then, survival analysis showed a negative correlation between SCHIP1 expression and overall survival in AML patients. And subgroup analysis showed that the expression of SCHIP1 in M0/M1/M2 was higher than that in M3/M6, regardless of age, gender or race. In addition, correlation analysis showed a weak correlation between SCHIP1 and FLT3 gene mutation, but no significant correlation with PML/RARα fusion, RAS activation and other risk factors. These results showed that SCHIP1 is highly expressed in acute myeloid leukemia (AML), and its high expression is significantly negatively correlated with overall survival of patients.Therefore, it can be used as a prognostic biomarker for the disease, and it is expected to become a precise therapeutic target for AML.